Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:ATECVE:EMHNASDAQ:PMNNASDAQ:SVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATEAntibe TherapeuticsC$0.00C$0.15▼C$1.23C$15.64M0.19135,475 shs167,044 shsEMHEmerald Health TherapeuticsC$0.26-3.8%C$0.26C$0.15▼C$0.53C$52.28MN/A644,760 shs384,329 shsPMNProMIS Neurosciences$0.49-2.0%$0.57$0.47▼$2.37$16.02M0.0277,267 shs55,602 shsSVASinovac Biotech$6.47$6.47$5.73▼$8.75$644.67M0.01N/AN/AInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATEAntibe Therapeutics0.00%0.00%0.00%0.00%0.00%EMHEmerald Health Therapeutics0.00%0.00%0.00%0.00%0.00%PMNProMIS Neurosciences-4.20%-5.15%-25.16%-38.51%-74.00%SVASinovac Biotech0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATEAntibe TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APMNProMIS Neurosciences3.2 of 5 stars3.55.00.00.03.50.80.6SVASinovac BiotechN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATEAntibe Therapeutics 0.00N/AN/AN/AEMHEmerald Health Therapeutics 0.00N/AN/AN/APMNProMIS Neurosciences 3.00Buy$4.50818.37% UpsideSVASinovac Biotech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ATE, SVA, EMH, and PMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025PMNProMIS NeurosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/1/2025PMNProMIS NeurosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATEAntibe TherapeuticsC$9.71M0.00N/A0.61C$0.49 per share0.00EMHEmerald Health TherapeuticsC$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64PMNProMIS NeurosciencesN/AN/AN/AN/A$0.20 per shareN/ASVASinovac Biotech$448.27M1.44$0.17 per share38.95$120.83 per share0.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATEAntibe Therapeutics-C$18.24M-C$0.35N/AN/AN/AN/A-52.72%-19.13%N/AEMHEmerald Health TherapeuticsN/A-C$0.70N/A∞N/AN/AN/AN/AN/APMNProMIS Neurosciences-$13.21M-$0.05N/AN/AN/AN/A-636.20%-130.32%8/14/2025 (Estimated)SVASinovac Biotech-$99.92MN/A0.00∞N/AN/AN/AN/AN/ALatest ATE, SVA, EMH, and PMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025PMNProMIS Neurosciences-$0.14-$0.21-$0.07-$0.21N/AN/A3/31/2025Q4 2024PMNProMIS Neurosciences-$0.14-$0.02+$0.12-$0.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATEAntibe TherapeuticsC$0.05N/AN/AN/A N/AEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/APMNProMIS NeurosciencesN/AN/AN/AN/AN/ASVASinovac BiotechN/AN/AN/AN/AN/ALatest ATE, SVA, EMH, and PMN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/1/2025SVASinovac Biotech--$55.005/23/20255/23/20256/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATEAntibe Therapeutics0.2910.069.58EMHEmerald Health Therapeutics35.452.972.61PMNProMIS NeurosciencesN/A9.309.30SVASinovac Biotech0.0111.3911.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATEAntibe TherapeuticsN/AEMHEmerald Health TherapeuticsN/APMNProMIS Neurosciences50.13%SVASinovac BiotechN/AInsider OwnershipCompanyInsider OwnershipATEAntibe Therapeutics7.94%EMHEmerald Health TherapeuticsN/APMNProMIS Neurosciences6.11%SVASinovac Biotech12.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATEAntibe Therapeutics1153.01 millionN/ANot OptionableEMHEmerald Health Therapeutics161205.03 millionN/ANot OptionablePMNProMIS Neurosciences532.69 million31.25 millionNot OptionableSVASinovac Biotech3,26199.64 million86.89 millionOptionableATE, SVA, EMH, and PMN HeadlinesRecent News About These CompaniesSINOVAC Receives Nasdaq Notification Regarding Late Filing of 2024 Annual ReportMay 22, 2025 | businesswire.comSinovac Biotech Calls Special Shareholder Meeting Amid Board ReshuffleMay 20, 2025 | tipranks.comSinovac Responds To Vivo's Hostile Actions And LawsuitsApril 30, 2025 | nasdaq.comSINOVAC Board Issues Letter to Shareholders to Set the Record Straight on the Hostile Actions and False Claims by Vivo CapitalApril 29, 2025 | businesswire.comSinovac Biotech shareholder announces legal proceedings regarding boardApril 24, 2025 | markets.businessinsider.comSinovac Not To Meet Annual Report Filing Deadline With SEC As Auditor Resigns; Calls For New BoardApril 23, 2025 | nasdaq.comVivo Capital Files Lawsuits to Protect Sinovac Shareholders from the New Board's Value Destructive ActionsApril 23, 2025 | businesswire.comSINOVAC Management Statement Regarding Auditor ResignationApril 22, 2025 | globenewswire.comSinovac Biotech Faces Audit Challenges Amid Board Legitimacy IssuesApril 21, 2025 | tipranks.comHeng Ren Urges Sinovac to Disclose Special Dividend Dates Proposes 41 Share Bonus PayoutApril 11, 2025 | msn.comSinovac BiotechApril 11, 2025 | vir.com.vnHeng Ren Urges Sinovac to Disclose Special Dividend Dates, Proposes $41/Share Bonus PayoutApril 11, 2025 | vir.com.vnHeng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the...April 10, 2025 | macaubusiness.comHeng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per ShareApril 10, 2025 | prnewswire.comSinovac Biotech to declare $55.00 per share special cash dividendApril 2, 2025 | markets.businessinsider.comSINOVAC Announces Decision to Declare Cash DividendApril 1, 2025 | businesswire.comSINOVAC Announces New Board Member and Chairman of the Audit CommitteeMarch 28, 2025 | businesswire.comSinovac shareholder urges transparency over COVID windfallMarch 24, 2025 | thepharmaletter.comHeng Ren ‘demands’ Sinovac Biotech distribute $8.9B in cash to shareholdersMarch 21, 2025 | finance.yahoo.comHeng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of TradingMarch 20, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesPalantir Scores First $1 Billion Contract; Is It Priced In?By Chris Markoch | May 27, 2025View Palantir Scores First $1 Billion Contract; Is It Priced In?Quantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationBy Leo Miller | May 27, 2025View Quantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationAXON: Competition Intensifies as Motorola Makes $4.4B AcquisitionBy Leo Miller | May 31, 2025View AXON: Competition Intensifies as Motorola Makes $4.4B AcquisitionD-Wave Pushes Back on Short Seller Case With Strong EarningsBy Nathan Reiff | May 14, 2025View D-Wave Pushes Back on Short Seller Case With Strong EarningsPalantir’s Latest Deal Could Put a Freeze on Its Stock PriceBy Chris Markoch | May 12, 2025View Palantir’s Latest Deal Could Put a Freeze on Its Stock PriceATE, SVA, EMH, and PMN Company DescriptionsAntibe Therapeutics TSE:ATEAntibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.Emerald Health Therapeutics CVE:EMHC$0.26 -0.01 (-3.77%) As of 04/26/2021Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.ProMIS Neurosciences NASDAQ:PMN$0.49 -0.01 (-2.00%) Closing price 03:59 PM EasternExtended Trading$0.49 0.00 (0.00%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Sinovac Biotech NASDAQ:SVASinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
